news Novel antibody candidate could offer pan-coronavirus protection 26 January 2021 | By Hannah Balfour (Drug Target Review) The lead candidate, ADG2, was able to neutralise SARS-CoV and various strains of SARS-CoV-2, including those that are resistant to currently available antibody treatments.